@prefix this: <http://purl.org/np/RApuVvBVyYxwEqsEEeOEgwJlEREo4ARm20OsT26gs8RMc> .
@prefix sub: <http://purl.org/np/RApuVvBVyYxwEqsEEeOEgwJlEREo4ARm20OsT26gs8RMc#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix dct: <http://purl.org/dc/terms/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_2983> bl:category bl:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_2983>;
    rdf:predicate bl:treats;
    rdf:subject <https://identifiers.org/drugbank:DB00887>;
    a rdf:Statement;
    rdfs:label "Bumetanide is contraindicated in anuria. Although bumetanide tablets can be used to induce diuresis in renal insufficiency, any marked increase in blood urea nitrogen or creatinine, or the development of oliguria during therapy of patients with progressive renal disease, is an indication for discontinuation of treatment with bumetanide tablets. Bumetanide is also contraindicated in patients in hepatic coma or in states of severe electrolyte depletion until the condition is improved or corrected. Bumetanide is contraindicated in patients hypersensitive to this drug.";
    bl:provided_by <https://w3id.org/um/NeuroDKG>;
    bl:relation schema:MedicalContraindication .
  
  <https://identifiers.org/drugbank:DB00887> bl:category bl:Drug .
}

sub:provenance {
  sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
    npx:hasSignature "IZumphNKrv/d3Q91ts1dpJjhYaWw2BgaTtDe8r2ccVnhLNLrPY4YffcLBY6B8hg5Y1kC31Porq57Lo2N4qce4KxSXorHiPfZpsjhocLmraM1Rq/t4FvRqm8sTr2q6/LeJN0ldjDqFaYChZAPe+d7aR0a9MjGojbSz9iQ2YjC5ao=";
    npx:hasSignatureTarget this: .
  
  this: dct:created "2021-08-23T19:12:45.253+02:00"^^xsd:dateTime;
    dct:creator orcid:0000-0002-1468-3557;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM>;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM>;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}